AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportRecursion Pharmaceuticals vs Abridge
VS
Recursion Pharmaceuticals
Enterprise
Abridge
Enterprise
Verdict by Category
Detailed category analysis is not available for this comparison.
Feature & Spec Matrix
Detailed Comparison27 Criteria
Complete side-by-side breakdown of specifications, capabilities, and feature parity
Swipe horizontally to compare features
Feature / Spec
Pricing Model
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
EnterpriseAbridge does not publish pricing and sells exclusively through enterprise contracts with health systems and hospital groups; there is no self-serve signup or individual-clinician plan. Third-party market analyses and reseller estimates place costs at roughly $200-$800+ per provider per month depending on integration depth (Epic, Oracle Health, or athenahealth), contract scale, and support level, with some estimates for full enterprise rollouts running $600-$1,200+ per provider per month. Implementation typically includes a multi-week to multi-month pilot and IT integration phase before system-wide deployment.
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
Institutional pilot programs and physician group demonstrations available
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Ambient clinical conversation recording, real-time structured medical note generation, and EHR charting for physicians
Enterprise & Scalability
Difference
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
Direct Epic/Cerner EHR deep integration, HIPAA & SOC2 Type II compliance, ambient conversation structuring into SOAP notes, and patient-facing summary translations
Core Categories
Difference
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare Tools
Recursion OS — AI-native end-to-end drug discovery platform integrating biology, chemistry, and clinical development
Difference
Recursion Pharmaceuticals Advantage
Not listed
Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Recursion Pharmaceuticals Advantage
Not listed
Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
Difference
Recursion Pharmaceuticals Advantage
Not listed
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Recursion Pharmaceuticals Advantage
Not listed
Recursion Data — phenomics and biology maps licensed to external researchers and pharma
Difference
Recursion Pharmaceuticals Advantage
Not listed
NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Difference
Recursion Pharmaceuticals Advantage
Not listed
Ambient, real-time capture of clinician-patient conversations
Difference
Not listed
Abridge Advantage
Auto-generated, billable clinical notes with EHR write-back
Difference
Not listed
Abridge Advantage
Linked evidence that traces each note statement back to the transcript
Difference
Not listed
Abridge Advantage
Native integration with Epic (Haiku, Canto, Hyperdrive), Oracle Health, and athenahealth
Difference
Not listed
Abridge Advantage
Coverage across 55+ specialties in outpatient, inpatient, and ED settings
Difference
Not listed
Abridge Advantage
Multi-language conversation recognition and note generation
Difference
Not listed
Abridge Advantage
Pre-visit patient history and prior-encounter summarization
Difference
Not listed
Abridge Advantage
HCC and problem-list capture aligned to billing codes
Difference
Not listed
Abridge Advantage
Enterprise admin console for access control and usage monitoring
Difference
Not listed
Abridge Advantage
HIPAA-compliant, SOC 2 and ISO 27001-certified infrastructure
Difference
Not listed
Abridge Advantage
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Abridge Pros & Cons
Pros
- Best in KLAS for Ambient AI two years running (2025 and 2026)
- Largest independent peer-reviewed study of any ambient AI scribe (NEJM AI, 1,300+ clinicians)
- Deep, native Epic integration across Haiku, Canto, and Hyperdrive
- Broad specialty coverage (55+) across outpatient, inpatient, and ED settings
- Strong enterprise security posture: HIPAA, SOC 2 Type II, ISO 27001
Cons
- No public pricing, free trial, or self-serve signup for individual clinicians
- Enterprise-only sales process that can take months to complete
- Reported documentation error rates (including some hallucinated content) still require clinician review
- No built-in patient communication, scheduling, or billing automation
- Not a realistic option for solo practitioners or small group practices
Head-to-Head Battle Cards
Popular Comparisons
Direct feature matrices, pricing breakdowns, and real-world benchmark duels
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare